B+
Bull case
30%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
AZTA
AzentaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that the May reset clears the deck: Sample Management still has resilient recurring pockets, UK Biocentre expands European sample-management capacity, liquidity remains strong, and a cleaner portfolio after B Medical plus better Multiomics execution could rebuild margins from depressed expectations.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Automated Stores rework costs and higher excess-and-obsolete inventory reserves are already hurting gross margin and could persist if execution does not improve.
Momentum
79
Value
60
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.00 · Bull $26.00 · Bear $14.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $34.80
Why
Momentum79 · Δ7d -8.9
Value60 · Δ7d -0.0
Sentiment20 · Δ7d +6.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Automated Stores rework costs and higher excess-and-obsolete inventory reserves are already hurting gross margin and could persist if execution does not improve.
- • Failure to close the B Medical Systems divestiture could force Azenta to keep operating a non-core asset longer, dilute results, and distract management.
- • The bear case is that the earnings miss was not just accounting noise: organic growth turned negative, North America sequencing demand and execution both weakened, goodwill impairment reflected lower fair-value assumptions, and the B Medical financing miss leaves another execution overhang while the long-range plan slips out to 2029.
Catalyst clock
2026-05-05
Q2 miss and FY26 guidance reset keep near-term pressure on the setup
Lead driver: Value · See fundamentals
Momentum
79
9% active weight
Current posture
7d trendSoftening
Δ7d
-8.9
Δ21d
-17.1
Value
60
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-1.1
Sentiment
20
62% active weight
Current posture
7d trendImproving
Δ7d
+6.2
Δ21d
+6.5
Why this grade
Composite grade F. Momentum 78.9 / Value 59.6 / Sentiment 20.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.47B
Beta
1.34
Shares Out
43.81M
P/E (TTM)
67.2
P/S (TTM)
2.77
P/FCF (TTM)
42.90
Rev YoY
+12.0%
EPS YoY
-105.2%
Gross Margin
+44.0%
Op Margin
-2.6%
Net Debt
-$283.35M
Current Ratio
2.50
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data